Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by bfwon Apr 30, 2019 12:14pm

91 Views

Post# 29689186

RE:RE:RE:RE:RE:Heavy volume all correlated with down trades

Yeah, that is probably a good guess.

My understanding is they have/had about 1 million shares of TH post Trogarzo launch.

So, they may have another couple hundred thousand to sell.

If this guess is correct, one would have to conclude that relations with Taimed are not good?

All the more reason to focus on Egrifta and NASH.

bfw

jeffm34 wrote: If I had to guess I think Taimed is most logical answer. They have more than enough shares. I think they are probably under some pressure too from their shareholders over slower than expected sales. I don't know if they would be using share sales to prop up their bottom line or send a message to TH.

Bullboard Posts

Sony’s Alpha 1 II: A new professional photography standard?